shlokn/autogkb huggingface dataset:
Article: Cytochrome P450 Genetic Variation Associated with Tamoxifen Biotransformation in American Indian and Alaska Native People
Gene: CYP2D6
Variant/haplotype: CYP2D6 poor metabolizer and intermediate metabolizer genotypes
Drug(s): 4-hydroxytamoxifen
Phenotype category: Metabolism/PK
Significant: no
Association: CYP2D6 poor metabolizer and intermediate metabolizer genotypes are not associated with concentrations of 4-hydroxytamoxifen in women with Breast Neoplasms.
Article: Pharmacogenetic Variants and Plasma Concentrations of Antiseizure Drugs: A Systematic Review and Meta-Analysis
Gene: CYP2C19
Variant/haplotype: CYP2C19 intermediate metabolizer
Drug(s): valproic acid
Phenotype category: Metabolism/PK
Significant: yes
Association: CYP2C19 intermediate metabolizer and poor metabolizer is associated with increased concentrations of valproic acid as compared to CYP2C19 normal metabolizer.
Notes: "Compared with the respective normal metabolizers, we observed increased valproate plasma concentrations in CYP2C9 intermediate metabolizers (12% [95% CI, 4%-20%]), CYP2C19 intermediate metabolizers (12% [95% CI, 2%-24%]) and CYP2C19 poor metabolizers (20% [95% CI, 2%-41%]) (Table 3)." "Abolished activity: CYP2C19*2: rs1799853 or CYP2C19*3: rs1057910"
Article: Association of Pharmacogenetic Markers with Premature Discontinuation of First-line Anti-HIV Therapy: An Observational Cohort Study
Gene: UGT1A1
Variant/haplotype: UGT1A1*1, UGT1A1*28
Drug(s): atazanavir / ritonavir
Phenotype category: Toxicity
Significant: yes
Association: UGT1A1 *28/*28 is associated with increased discontinuation of atazanavir / ritonavir in people with HIV Infections as compared to UGT1A1 *1/*1.
Notes: Atazanavir boosted with ritonavir. Treatment discontinuation in the first year was investigated. The drug discontinuation was mainly due to drug toxicity. Carriers of the UGT1A1 *28/*28 (TA)7/(TA)7 and UGT1A1 *28/*37 (TA)7(TA)8 (homozygous decreased function) experience more drug discontinuation due to toxicity (not further specified) than *1/*28 and *1/*1 carriers (p=0.004). 2 of 3 individuals homozygous for the UGT1A1 *28 discontinued atazanavir in the present study (although hyperbilirubinemia was not listed as the cause but "drug toxicity" often was).
Article: Neurotrophic Tyrosine Kinase Receptor Type 2 (NTRK2) Gene Associated with Treatment Response to Mood Stabilizers in Patients with Bipolar I Disorder
Variant/haplotype: rs2769605
Drug(s): lithium, valproic acid
Phenotype category: Efficacy
Significant: yes
Association: Genotype CC is associated with decreased response to lithium or valproic acid in people with Bipolar Disorder as compared to genotypes CT + TT.
Article: Pharmacogenetic Influence of LOC387715/HTRA1 on the Efficacy of Bevacizumab Treatment for Age-Related Macular Degeneration in a Korean Population
Gene: CFH
Variant/haplotype: rs1061170
Drug(s): bevacizumab
Phenotype category: Dosage
Significant: yes
Association: Genotype CT is associated with increased dose of bevacizumab in people with Macular Degeneration as compared to genotype TT.
Notes: Patients with the CT genotype were given a greater average number of additional bevacizumab injections (after the initial three intravitreal injections), as compared to those with the TT genotype.
Article: Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants?
Gene: TPMT
Variant/haplotype: TPMT*1, TPMT*3C
Drug(s): mercaptopurine
Phenotype category: Dosage, Toxicity
Significant: no
Association: TPMT *1/*3C is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.
Notes: as measured by 6-MP dose intensity, which is a measure dose adjustment due to toxicity calculated by the ratio of the prescribed 6-MP dose over the protocol dose of 50 mg/m2/d. There were no TPMT*3C homozygotes and no TPMT*2.
Article: Influences of Organic Cation Transporter Polymorphisms on the Population Pharmacokinetics of Metformin in Healthy Subjects
Gene: SLC22A2
Variant/haplotype: rs316019
Drug(s): metformin
Phenotype category: Metabolism/PK
Significant: yes
Association: Genotype CC is associated with increased clearance of metformin in healthy individuals as compared to genotype AC.
Notes: Healthy individuals with the CC genotype had decreased area under the serum concentration-time curve from zero to infinity (AUCinf), decreased peak concentration (Cmax), and increased clearance (CL/F) of metformin, as compared to those with the AC genotype. Please note alleles have been complemented to the plus chromosomal strand.
Article: Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age
Gene: CYP2A6
Variant/haplotype: CYP2A6*1, CYP2A6*35
Drug(s): letrozole
Significant: not stated
Association: CYP2A6 *1/*35 is associated with metabolism of letrozole in women with Breast Neoplasms.
Notes: CYP2A6*1/*35 is associated with normal metabolism of letrozole (compared to slow metabolism of nicotine).
Article: The Pharmacogenetics of Cannabis in the Treatment of Chronic Pain
Gene: UGT2B7
Variant/haplotype: rs7438135
Drug(s): cannabinoids
Phenotype category: Efficacy
Significant: yes
Association: Genotype AA is associated with increased clinical benefit to cannabinoids in people with Pain as compared to genotypes AG + GG.
Notes: "AA homozygous patients for the UGT2B7 gene reported an average pain decrease of 2 VAS points, compared to the 1.3 VAS points of GG homozygotes or AG heterozygotes."
Article: Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer
Gene: CYP2D6
Variant/haplotype: CYP2D6 poor metabolizers
Drug(s): endoxifen
Phenotype category: Metabolism/PK
Significant: yes
Association: CYP2D6 poor metabolizer is associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizer.
Notes: Strong gene-dose effect for an association between the CYP2D6 activity score and endoxifen concentrations in all ethnic cohorts. *3, *4, *5, *6, *9, *10, *14, *15, *17, *41 were detected and grouped the following: PM/PM (0), PM/IM (0.5), IM/IM (0.75), PM/EM (1), IM/EM (1.5), EM/EM (2) and EM/UM (3). Patients were treated with tamoxifen but also 80% received chemotherapy. [pre-menopausal] [adjuvant] [DNA source: blood] [HWE: yes except *3, *9, *10, *17 in some populations]
Article: Pharmacogenomics of Hypertension: A Genome‐Wide, Placebo‐Controlled Cross‐Over Study, Using Four Classes of Antihypertensive Drugs
Gene: ACY3
Variant/haplotype: rs2514036
Drug(s): bisoprolol
Phenotype category: Efficacy
Significant: yes
Association: Allele T is associated with increased response to bisoprolol in men with Hypertension as compared to allele C.
Notes: Because of the GWAS design, these p-values are suggestive, not significant. Each participant received losartan 50 mg, bisoprolol 5 mg, hydrochlorothiazide 25 mg, and amlodipine 5 mg daily, each as a monotherapy in randomized order for 4 weeks. The study started with a 4-week run-in placebo period, and all 4 drug treatments were separated by 4-week placebo periods. 24-hour ABP readings were recorded at the end of each treatment period.
Article: Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors
Gene: CYP3A5
Variant/haplotype: CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7
Drug(s): atazanavir
Phenotype category: Metabolism/PK
Significant: yes
Association: CYP3A5 *3 + *6 + *7 are associated with decreased metabolism of atazanavir in healthy individuals as compared to CYP3A5 *1.
Notes: In this two-phase study, healthy participants were given atazanavir only for 7 days and then were co-administered ritonavir as a booster for days 8-14. The results here are for day 1-7 (atazanavir alone). Non-expressor status was assigned to CYP3A5 homozygous variants (*3, *6, or *7) and expressor status was assigned to those carrying at least one *1 allele. By the end of day 7 oral clearance of atazanavir was 0.25 L/h/kg in CYP3A5 expressors versus 0.18 L/hr/kg in non-expressors (a 1.39 faster fold faster clearance in CYP3A5 expressors). Note: the authors do not specify which *3 allele patients had and so *3a here represents all *3 alleles.
Article: Polymorphisms of the Proinflammatory Cytokine Genes Modulate the Response to NSAIDs but Not to Triptans in Migraine Attacks
Gene: IL1B
Variant/haplotype: rs16944
Drug(s): aspirin, diclofenac, ibuprofen, indomethacin, ketorolac, naproxen
Phenotype category: Efficacy
Significant: no
Association: Allele G is not associated with clinical benefit to aspirin, diclofenac, ibuprofen, indomethacin, ketorolac or naproxen in people with Migraine without Aura as compared to allele A.
Notes: Please note that alleles have been complemented to the positive strand.
Article: Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients
Gene: CYP3A4
Variant/haplotype: CYP3A4*1, CYP3A4*22
Drug(s): tacrolimus
Phenotype category: Metabolism/PK
Significant: no
Association: CYP3A4 *22 is not associated with clearance of tacrolimus in people with liver transplantation as compared to CYP3A4 *1.
Article: Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole
Gene: CYP2D6
Variant/haplotype: CYP2D6 poor metabolizer
Drug(s): tolterodine
Phenotype category: Metabolism/PK
Significant: not stated
Association: CYP2D6 poor metabolizer is associated with increased concentrations of tolterodine in men as compared to CYP2D6 normal metabolizer.
Notes: Subjects were phenotyped with debrisoquine. Serum concentrations of the active 5-hydroxymethyl metabolite of tolterodine, 5-HM, were not quantifiable in PMs. "There was a clear difference between the two CYP2D6 phenotypes, with the mean concentrations of tolterodine being 5–10 times higher in PMs compared with those in EMs. Serum 5-HM concentrations were in the same range as the parent compound in EM"
Article: Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients
Gene: EPHX1
Variant/haplotype: rs1051740
Drug(s): carbamazepine
Phenotype category: Metabolism/PK
Significant: yes
Association: Genotype CC is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.
Notes: The authors evaluated maintenance dose-adjusted concentrations of carbamazepine (CBZ), its active metabolite, CBZ-epoxide (CBZE), and its inactive metabolite CBZ-diol (CBZD) as well as CBZE:CBZ, CBZD:CBZ and CBZD:CBZE ratios.The CC genotype is associated with a lower mean dose adj. concentration  of carbamazepine (CBZ) (microgram/mL per mg/Kg) (0.76 for the CC genotype vs. 0.94 &1.02 for the TT and CT genotypes, respectively). The C allele was also associated with a lower mean CBZ-diol to CBZ ratio (0.31 for TT vs. 0.23 & 0.25 for the CT & CC genotypes, respectively).
Article: Genetic Polymorphisms of ENPP2 Are Possibly Associated with Pain Severity and Opioid Dose Requirements in Patients with Inflammatory Pain Conditions: Clinical Observation Study
Gene: ENPP2
Variant/haplotype: rs2249015
Drug(s): opioids
Phenotype category: Dosage
Significant: yes
Association: Genotype AA is associated with increased dose of opioids in people with Pain, Postoperative as compared to genotypes AG + GG.
Notes: authors describe for minor allele, all sources in gnomAD give A as minor allele and G as major allele. This was not significant for dosage in the cancer pain intensity cohort.
Article: Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy
Gene: CYP19A1
Variant/haplotype: rs1008805
Drug(s): hdl cholesterol
Phenotype category: Other
Significant: yes
Association: Allele G is associated with decreased concentrations of hdl cholesterol in women with Breast Neoplasms and Menopause as compared to allele A.
Notes: when taking letrozole and lipid lowering agents (LLA), such as statins. Data are from a sub-analysis of the Exemestane and Letrozole Pharmacogenomics (ELPh) study, where post-menopausal women with early stage breast cancer were randomized to receive exemestane or letrozole. Of the 303 eligible women, 160 were randomized to the letrozole group, 52 of whom were also taking LLA. This SNP was associated with decreases in HDL-cholesterol of 6.6 mg/dL (SE 1.7).
Article: Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population
Gene: CYP4F2
Variant/haplotype: rs2108622
Drug(s): warfarin
Phenotype category: Dosage
Significant: no
Association: Allele T is not associated with dose of warfarin as compared to allele C.
Notes: Neither the addition of race, number of concurrent medications nor the number of concurrent medications interacting with warfarin enhanced algorithm performance. Similarly, consideration of CYP4F2, CALU or GGCX variant genotypes did not improve algorithms.
Article: Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking
Gene: CHRNA5
Variant/haplotype: rs588765
Drug(s): nicotine
Phenotype category: Dosage
Significant: no
Association: Allele C is not associated with dose of nicotine in people with Tobacco Use Disorder as compared to allele T.
Article: Genetic Determinants of Response to Warfarin during Initial Anticoagulation
Gene: CYP2C9
Variant/haplotype: CYP2C9*1
Drug(s): warfarin
Phenotype category: Dosage
Significant: yes
Association: CYP2C9 *1/*1 is associated with increased dose of warfarin.
Notes: as compared to *2*2 or *3*3 or *2*3 with *1*2 and *1*3 requiring intermediate doses. This was most marked at day 28 to end of follow-up with average doses of 5.18mg/day for *1*1, 4.25mg/day for *1*2 or *1*3 and 3.36mg/day for *2*2 or *3*3 or *2*3.
Article: Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance
Gene: ABCB1
Variant/haplotype: rs1128503
Drug(s): donepezil
Phenotype category: Metabolism/PK
Significant: no
Association: Genotype AA is not associated with clearance of donepezil in people with Alzheimer Disease as compared to genotype GG.
Notes: Genotypes of AA, AG and GG did not influence donepezil clearance in a covariate model. Alleles have been complemented to the plus chromosomal strand.
Article: Genome-Wide Meta-Analysis of Cotinine Levels in Cigarette Smokers Identifies Locus at 4q13.2
Gene: CHRNB4
Variant/haplotype: rs10851907
Drug(s): cotinine
Phenotype category: Metabolism/PK
Significant: yes
Association: Allele A is associated with increased concentrations of cotinine in people with Tobacco Use Disorder as compared to allele G.
Notes: The authors conducted a GWAS meta-analysis to identify genetic variants associated with cotinine in current daily smokers (Caucasian). The following study cohorts were analyzed: ALSPAC, CARDIA, FinnTwin, Framingham, GenMets, MESA, NESDA, NTR, TwinsUK, YFS. The SNP was associated with a ~34 ng/ml increase in plasma/serum cotinine and accounted for 1.75% variance in cotinine levels.
Article: Pharmacogenetic Influence on Stereoselective Steady-State Disposition of Bupropion
Gene: CYP2C19
Variant/haplotype: CYP2C19 poor metabolizer
Drug(s): bupropion
Phenotype category: Metabolism/PK
Significant: no
Association: CYP2C19 poor metabolizer is not associated with increased exposure to bupropion in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizer.
Notes: "CYP2C19 phenotype had no influence on bupropion enantiomers apparent oral; clearance or renal clearance, and also had no influence on bupropion hydroxylation, based on; enantiomers plasma hydroxybupropion/bupropion AUC ratios (not shown) or urine; hydroxybupropion formation clearances. The plasma racemic threohydrobupropion/racemic; bupropion AUC ratio was greater in CYP2C19 intermediate and poor metabolizers, due mainly; to a greater 1S,2S-threohydrobupropion/S-bupropion AUC ratio. Formation clearance of 4-; hydroxy(erythro- and threo-hydrobupropion) was also significantly less in CYP2C19 poor; metabolizers. These were not greater in ultrarapid metabolizers. "
Article: Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in post-menopausal patients with breast cancer
Gene: CYP3A4
Variant/haplotype: rs2242480
Drug(s): exemestane
Phenotype category: Metabolism/PK
Significant: no
Association: Genotypes C/T + T/T are not associated with concentrations of exemestane in women with Breast Neoplasms as compared to genotype C/C.
Notes: No significant difference in exemestane concentrations were seen between the three genotypes. The publication reports the finding for CYP3A4*1G. PharmVar re-assigned CYP3A4*1G to CYP3A4*36. Previously, this annotation used CYP3A4*36 which has been retired by PharmVar. All references to *36 have been replaced by rs2242480 alleles.
Article: Effects of CYP2C19 Loss-of-Function Variants on the Eradication of H. pylori Infection in Patients Treated with Proton Pump Inhibitor-Based Triple Therapy Regimens: A Meta-Analysis of Randomized Clinical Trials
Gene: CYP2C19
Variant/haplotype: CYP2C19*1, CYP2C19*2, CYP2C19*3
Drug(s): omeprazole
Phenotype category: Efficacy
Significant: yes
Association: CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.
Notes: Subjects with the *1/*1 genotype had a significantly lower eradication rate of Helicobacter pylori (H. pylori), as compared to those with the *2/*2, *2/*3 or *3/*3 genotype. This was a meta-analysis and included 6 studies. Patients were treated with the drugs anywhere from 7-14 days, and also received the antibiotics amoxicillin and clarithromycin as part of triple therapy.
Article: Combined study of genetic and epigenetic biomarker risperidone treatment efficacy in Chinese Han schizophrenia patients
Gene: HTR2A
Variant/haplotype: rs6313
Drug(s): risperidone
Phenotype category: Efficacy
Significant: no
Association: Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G.
Notes: Please note that alleles have been complemented to the positive strand.
Article: Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response
Variant/haplotype: rs1908557
Drug(s): bupropion
Phenotype category: Efficacy
Significant: yes
Association: Allele C is associated with decreased response to bupropion in people with Depression as compared to allele T.
Article: Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction
Gene: NTRK2
Variant/haplotype: rs2120266
Drug(s): methadone
Phenotype category: Dosage
Significant: no
Association: Genotype AA is associated with increased dose of methadone in people with Heroin Dependence as compared to genotypes AG + GG.
Notes: This association was not statistically significant after permutation analysis based on 40,000 replicates, and not statistically significant after adjusting for testing for multiple SNPs (Bonferroni correction).
Article: Pharmacogenomics of celiprolol – evidence for a role of P‐glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokinetics
Gene: ABCB1
Variant/haplotype: rs1045642
Drug(s): celiprolol
Phenotype category: Metabolism/PK
Significant: yes
Association: Allele G is associated with decreased concentrations of Celiprolol in healthy individuals as compared to allele A.
Notes: "the AUC0-infinity values were 213% smaller (p < 5 × 10−3) per copy of the ABCB1 c.3435T>C minor allele". Alleles complemented to plus chromosomal strand.
Article: Genomewide Association Study Identifies Novel Genetic Loci That Modify Antiplatelet Effects and Pharmacokinetics of Clopidogrel
Gene: CYP2C19
Variant/haplotype: CYP2C19*1, CYP2C19*2
Drug(s): clopidogrel
Phenotype category: Metabolism/PK
Significant: yes
Association: CYP2C19 *2 is associated with decreased metabolism of clopidogrel as compared to CYP2C19 *1/*1.
Notes: This variant was associated with decreased active metabolite H4 concentration.
Article: The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients
Gene: UGT1A1
Variant/haplotype: rs887829
Drug(s): warfarin
Phenotype category: Dosage
Significant: no
Association: Allele C is not associated with dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to allele T.
Article: Genotype-guided dosing study of FOLFIRI plus bevacizumab in metastatic colorectal cancer patients
Gene: UGT1A1
Variant/haplotype: UGT1A1*1, UGT1A1*28
Drug(s): irinotecan
Phenotype category: Dosage
Significant: not stated
Association: UGT1A1 *1/*28 is associated with decreased dose of irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.
Notes: This study provided maximum tolerated doses of irinotecan for the *1/*1 and *1/*28 genotypes. Patients with *28/*28 were excluded. The maximum tolerated dose for *1/*1 was higher than that of *1/*28, and both were higher than the standard dose of 180 mg/m2.
Article: Underlying genetic structure impacts the association between CYP2B6 polymorphisms and response to efavirenz and nevirapine
Gene: CYP2B6
Variant/haplotype: rs8192709
Drug(s): efavirenz, non-nucleoside reverse transcriptase inhibitors
Phenotype category: Efficacy
Significant: no
Association: Genotype CT is not associated with response to efavirenz or non-nucleoside reverse transcriptase inhibitors in women with HIV Infections as compared to genotype CC.
Article: Candidate‐Gene Study of Functional Polymorphisms in SLCO1B1 and CYP3A4/5 and the Cholesterol‐Lowering Response to Simvastatin
Gene: CYP3A5
Variant/haplotype: CYP3A5*1, CYP3A5*3
Drug(s): simvastatin
Phenotype category: Efficacy
Significant: no
Association: CYP3A5 *3 is not associated with response to simvastatin as compared to CYP3A5 *1.
Notes: 609 self-reported white and 335 self-reported African American men and women with baseline total serum cholesterol level between 160 and 400 mg/dL received 40 mg simvastatin daily for 6 weeks. Clinic visits occurred at 2-week intervals during the 6-week study.
Article: Pharmacogenetic Variants Associated with Fluoxetine Pharmacokinetics from a Bioequivalence Study in Healthy Subjects
Gene: CYP2D6
Variant/haplotype: rs28371703
Drug(s): fluoxetine
Phenotype category: Metabolism/PK
Significant: yes
Association: Genotype GT is associated with increased half-life time of fluoxetine in healthy individuals as compared to genotype GG.
Notes: "Stratification of subjects based on CYP2D6 genotypes confirmed the difference in the PK profiles, based on the three SNVs found in this study (rs1065852, rs1135840, and rs28371703)" Alleles complemented.
Article: Single Nucleotide Polymorphisms of CYP3A4 and CYP3A5 in Romanian Kidney Transplant Recipients: Effect on Tacrolimus Pharmacokinetics in a Single-Center Experience
Gene: CYP3A5
Variant/haplotype: CYP3A5*1, CYP3A5*3
Drug(s): tacrolimus
Phenotype category: Metabolism/PK
Significant: yes
Association: CYP3A5 *1/*1 + *1/*3 is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.
Notes: " In the case of the CYP3A5*1 allele, a significant difference in the C0/D ratio was observed between carriers (CYP3A5*1/*1 and CYP3A5*1/*3) and individuals with the CYP3A5*3/*3 genotype during all post-transplant phases (p < 0.001)"